Nagashree Seetharamu, MD
Internal Medicine · New Hyde Park, NYNPI 1124198833
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,139 of the $79,764 with a category attached, or 77.9%. It is spread thinly across 21 manufacturers, the largest accounting for just 21.8%. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $1009.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Coherus Oncology, Inc.$10K
- Amgen$9K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Eisai Inc.$5K
- EMD Serono, Inc.$4K
- plus $25K from 15 others
Across 216 payments — averaging $11,065 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.1M
- E.r. Squibb & Sons, L.L.C.$459K
- Genentech, Inc.$309K
- AVEO Pharmaceuticals, Inc.$109K
- Boehringer Ingelheim Pharma GmbH & Co.kg$105K
- AbbVie$78K
- plus $239K from 7 others
What the payments were for
- Consulting fees$62,13978%
- Speaking & faculty fees$12,24115%
- Travel & lodging$3,1404%
- Food & beverage$2,1323%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $17,407 |
| Coherus Oncology, Inc. | 4 | $9,741 |
| Amgen | 10 | $9,459 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $8,857 |
| Eisai Inc. | 4 | $5,325 |
| EMD Serono, Inc. | 5 | $4,238 |
| Janssen Scientific Affairs, LLC | 3 | $3,908 |
| Genentech USA, Inc. | 5 | $3,833 |
| AbbVie | 1 | $2,900 |
| Pfizer | 2 | $2,600 |
| Nuvation Bio Inc. | 1 | $2,520 |
| Boehringer Ingelheim | 2 | $2,500 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,293 |
| Blueprint Medicines Corporation | 1 | $2,016 |
| Novocure Inc. | 2 | $699 |
| Jazz Pharmaceuticals Inc. | 5 | $572 |
| Array Biopharma Inc | 1 | $500 |
| Daiichi Sankyo Inc. | 2 | $198 |
| Genentech, Inc. | 1 | $100 |
| Galvanize Therapeutics, Inc | 1 | $74 |
| Lilly USA, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,764 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 135 | $2,349,047 |
| AlecensaAlectinib Hcl | 31 | $465,971 |
| TabrectaCapmatinib Hydrochloride | 14 | $236,836 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 27 | $235,663 |
| MekinistTrametinib Dimethyl Sulfoxide | 34 | $205,441 |
| TafinlarDabrafenib Mesylate | 19 | $146,041 |
| RetevmoSelpercatinib | 11 | $69,049 |
| EliquisApixaban | 15 | $11,945 |
| Gabapentin | 24 | $372 |
| Oxycodone Hcl | 17 | $363 |
| Dexamethasone | 27 | $219 |
| Metoclopramide Hcl | 41 | $178 |
| Levothyroxine Sodium | 16 | $125 |
| Folic Acid | 22 | $59 |
| Prednisone | 31 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $17,407 | $2,349,047135 claims |
| Genentech USA, Inc.Alecensa | $3,833 | $465,97131 claims |
| Lilly USA, LLCRetevmo | $26 | $69,04911 claims |
| PfizerEliquis | $2,600 | $11,94515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New Hyde Park
- Joshua SternNew Hyde Park$126K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.